Spotlight On ATTR-CM
Welcome to Spotlight On ATTR-CM, your go-to source for the latest research, diagnostic advancements, and therapeutic strategies in transthyretin amyloid cardiomyopathy (ATTR-CM). Join leading cardiologists and researchers as they share their insights on this intricate condition to enhance patient care and outcomes.
1-15 of 27
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart MattersTreating ATTR-CM Early: A Shift From Reactive to Strategic Care
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Heart MattersAdvancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
AudioAbstractsExploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Heart MattersUnderstanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Heart MattersATTR-CM Trials Revisited: A Broader View of Treatment Benefit
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
AudioAbstractsFrom HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
- advertisement
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
AudioAbstractsManaging Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
Diagnostic Gaps in ATTR-CM: Insights from a Multispecialty Survey in France
Heart MattersDiagnostic Gaps in ATTR-CM: Insights from a Multispecialty Survey in France
ATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
Heart MattersATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Heart MattersTimely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Heart MattersEquitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Heart MattersTranslating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
- advertisement
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Heart MattersStaging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Analyzing Outpatient Worsening Heart Failure in ATTR-CM
Heart MattersAnalyzing Outpatient Worsening Heart Failure in ATTR-CM
Current and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
Heart MattersCurrent and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy









































